ACETO Reports Fiscal 2014 Fourth Quarter and Year End Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aceto Corp (ACET) Tops Q3 EPS by 4c
September 4, 2014 5:01 PM EDTAceto Corp (NASDAQ: ACET) reported Q3 EPS of $0.21, $0.04 better than the analyst estimate of $0.17. Revenue for the quarter came in at $139.6 million versus the consensus estimate of $134.23 million.
"ACETO made significant progress during fiscal 2014 toward our long-term strategy of becoming a more human health-oriented company. An expanded and enhanced management team at our generic drug division, Rising Pharmaceuticals, the acquisition of the generic pharmaceutical company, PACK Pharmaceuticals, including its robust product pipeline, new finished dose product launches and a near doubling of research and development spend versus fiscal 2013 all contributed to this progress.... More
